Leaders Apoptosis in haematological malignancies

In recent years, there has been a considerable effort to understand the mechanisms by which cells cause their own demise. This process, known as programmed cell death or apoptosis, is an important regulatory mechanism in normal tissue development and homeostasis. Abnormalities in apoptotic pathways contribute to a diverse array of pathological processes including cancer, immune disorders, and neurodegenerative diseases.' The haematopoietic system provides many examples of the significance of apoptosis, both as a regulatory mechanism under normal conditions, and as a pathogenetic element in neoplasia. 6̀ Specifically, acquired resistance to apoptosis can both facilitate the development of haematological malignancies and render these tumours resistant to therapy. This review highlights several examples illustrating the significance of apoptosis in haematological malignancies.

[1]  Frequent p 53 Gene Mutations in Blast Crisis of Chronic Myelogenous Leukemia , Especially in Myeloid Crisis Harboring Loss of a Chromosome 17 p 1 , 2007 .

[2]  H. Koeffler.  p 53 in Hematologic Malignancies , 2002 .

[3]  N. Young,et al.  Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. , 1997, Blood.

[4]  P. Venugopal,et al.  Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. , 1996, Blood.

[5]  Joseph A. DiGiuseppe,et al.  Multiparameter flow-cytometric analysis of bcl-2 and Fas expression in normal and neoplastic hematopoiesis. , 1996, American journal of clinical pathology.

[6]  E. Schattner,et al.  CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells. , 1996, Blood.

[7]  S. Korsmeyer,et al.  Molecular thanatopsis: a discourse on the BCL2 family and cell death. , 1996, Blood.

[8]  F. Mandelli,et al.  Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. Beutler,et al.  The tumor necrosis factor ligand and receptor families. , 1996, The New England journal of medicine.

[10]  J. Lotem,et al.  Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. , 1996, Leukemia.

[11]  W. Chan,et al.  p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. , 1996, Blood.

[12]  L. Sachs,et al.  The control of hematopoiesis and leukemia: from basic biology to the clinic. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  F. Bosch,et al.  p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. , 1996, Blood.

[14]  T. McDonnell,et al.  Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. , 1996, Journal of immunology.

[15]  John Calvin Reed,et al.  Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. , 1996, Oncogene.

[16]  J. Lotem,et al.  Protection of human myeloid leukemic cells against doxorubicin-induced apoptosis by granulocyte-macrophage colony-stimulating factor and interleukin 3. , 1996, Leukemia.

[17]  F. Behm,et al.  Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. , 1996, Blood.

[18]  J. Shuster,et al.  High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. , 1996, Blood.

[19]  J. Bertoglio,et al.  BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells. , 1996, Blood.

[20]  F. Behm,et al.  Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. , 1996, The Journal of clinical investigation.

[21]  T. McDonnell,et al.  Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. , 1996, Leukemia.

[22]  P. Greenberg,et al.  Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. , 1996, Blood.

[23]  Y. Komada,et al.  Fas receptor (CD95)-mediated apoptosis is induced in leukemic cells entering G1B compartment of the cell cycle. , 1995, Blood.

[24]  F. Birg,et al.  Search for rearrangements and/or allelic loss of the fas/APO-1 gene in 101 human lymphomas. , 1995, American journal of clinical pathology.

[25]  D. Cortez,et al.  Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis , 1995, Molecular and cellular biology.

[26]  F. Birg,et al.  Frequent expression of FAS/APO‐1 in Hodgkin's disease and anaplastic large cell lymphomas FAS/APO‐1 in Hodgkin's disease and anaplastic large cell lymphomas , 1995, Histopathology.

[27]  W. El-Deiry,et al.  BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. , 1995, Blood.

[28]  H. Preisler,et al.  Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. , 1995, Blood.

[29]  S. Dower,et al.  Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. , 1995, Blood.

[30]  F. Rieux-Laucat,et al.  Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. , 1995, Science.

[31]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[32]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[33]  H. Preisler,et al.  Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis , 1995, American journal of hematology.

[34]  A. Bedi,et al.  Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis. , 1995, Cancer research.

[35]  B. Quesnel,et al.  p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .

[36]  T. Yoshino,et al.  Expression of Bcl-2 protein and Fas antigen in non-Hodgkin's lymphomas. , 1994, The American journal of pathology.

[37]  M. Kitagawa,et al.  p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia. , 1994, The American journal of pathology.

[38]  M. Hsiao,et al.  Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase. , 1994, Blood.

[39]  B. Zehnbauer,et al.  Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. , 1994, Blood.

[40]  T G Cotter,et al.  BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. , 1994, Blood.

[41]  S. Korsmeyer,et al.  Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair , 1993, Cell.

[42]  D. Longo,et al.  p53 mutation is associated with progression in follicular lymphomas. , 1993, Blood.

[43]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[44]  J. Lotem,et al.  Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. , 1993, Blood.

[45]  N. Russell,et al.  Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia. , 1993, Blood.

[46]  S. Nagata,et al.  Effect of bcl-2 on Fas antigen-mediated cell death. , 1993, Journal of immunology.

[47]  J. Lotem,et al.  Control of programmed cell death in normal and leukemic cells: new implications for therapy. , 1993, Blood.

[48]  T. Waldmann,et al.  APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia. , 1993, Blood.

[49]  J. Magaud,et al.  High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. , 1993, Blood.

[50]  Koichi Sugimoto,et al.  Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. , 1993, Blood.

[51]  W. van Putten,et al.  Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. , 1993, The New England journal of medicine.

[52]  John Calvin Reed,et al.  Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. , 1993, Blood.

[53]  K. Offit,et al.  p53 mutations are associated with histologic transformation of follicular lymphoma. , 1993, Blood.

[54]  S. Korsmeyer.  Bcl-2 initiates a new category of oncogenes: regulators of cell death. , 1992, Blood.

[55]  J. Lotem,et al.  Rescue from programmed cell death in leukemic and normal myeloid cells. , 1991, Blood.

[56]  T. McDonnell,et al.  Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) , 1991, Nature.

[57]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[58]  T. Dexter,et al.  Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis , 1990, Nature.

[59]  S. Korsmeyer,et al.  bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.

[60]  J.,et al.  Clinical Significance of p 53 Mutations in Relapsed T-cell Acute Lymphoblastic Leukemia , 2022 .